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There has been widespread support for harm reduction programs as an essential component for responding to the
HIV and illicit drug use epidemics. However, despite the growing international acceptance of harm reduction, there
continues to be strong opposition to this approach, with critics alleging that harm reduction programs enable drug
use. Vancouver, Canada provides a compelling case study that demonstrates that many positive impacts of harm
reduction can be attained while addiction treatment-related goals are simultaneously supported. While the evidence
for harm reduction is clearly mounting, it is unfortunate that ideological and political barriers to implementing harm
reduction programs in Canada remain. As evidenced by Vancouver and elsewhere, harm reduction programs do not
exacerbate drug use and undermine treatment efforts and should thereby occupy a well-deserved space within the
continuum of programs and services offered to people who inject drugs.
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Background
The widespread support for harm reduction programs as
essential responses to the harms of illicit drug use con-
tinues to grow [1]. International health bodies, including
the World Health Organization (WHO) and the Joint
United Nations Programme on HIV/AIDS (UNAIDS),
recommend harm reduction programs as best practices
and crucial for reducing HIV infection among people
who inject drugs (IDU) [1]. The WHO/UNAIDS com-
prehensive HIV prevention package for the prevention,
treatment, and care of HIV among IDU recommends the
provision of sterile needles and syringes as well as opioid
substitution therapy, and in response, public health and
nongovernmental organizations in various settings have
rolled out these programs [2,3].
However, despite the growing international acceptance
of harm reduction approaches as an evidence-based stra-
tegy for minimizing the negative consequences related
to illicit drug use, opposition to harm reduction persists.
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injecting facilities (SIFs) enable drug use and undermine
drug treatment efforts [4]. However, much of these argu-
ments have relied on unpublished reports by anti-drug
lobby groups and have been deemed questionable for fail-
ing to meet accepted academic standards [5,6].
However, as such criticisms and concern continue to
be aired and repeated by some media outlets [7], the evi-
dence in support of harm reduction continues to grow,
as does the body of research demonstrating that harm
reduction does not enable drug use at the individual nor
the community level. The city of Vancouver (Canada)
provides an interesting case example of such effects. In
the late 1990s, Vancouver was the site of massive epi-
demics of HIV infection and overdose among IDU. In
response, the regional health authority launched an ag-
gressive public health response, which included scaling
up syringe distribution, peer-based programming, me-
thadone maintenance therapy, and establishing the first
North American sanctioned SIF. A recent report exam-
ining data derived from three US National Institute of
Drug Abuse-funded cohort studies revealed that rates of
HIV and HCV infection as well as other indicators of
drug-related risks and harms have plummeted in Van-
couver over the past 15 years [8]. For example, syringetd. This is an Open Access article distributed under the terms of the Creative
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1996 to less than 2% in 2011, and this can be largely
attributed to an increase in the distribution of sterile
injecting paraphernalia [8]. At the same time, there has
been a dramatic increase in drug injection cessation
among IDU in this setting. As the report also shows,
these health gains have been made despite the failure of
drug supply reduction efforts, evidenced by the fact that
the accessibility and price of illicit drugs have remained
stable in Vancouver for over 10 years [8].
While it is clear that local policy makers in Vancouver
have been convinced of the value of harm reduction
programs, sadly, it appears that the federal conservative
government of Canada has chosen to ignore evidence
and embrace a drug policy approach that is not only
costly but also ineffective in reducing illicit drug use and
supply [8,9]. Such unsuccessful policies continue to place
undue harm upon IDU by placing an emphasis on failed
law enforcement approaches in combatting illicit drug
use [10,11]. Further, for the first time since 1987, the
words ‘harm reduction’ have been removed from Canada’s
national drug strategy [12]. The federal government has
also remained opposed to Insite, Vancouver’s SIF. How-
ever, despite their numerous attempts to shut the facility
down, a unanimous 9-0 Supreme Court ruling has allowed
this life-saving program to continue to operate under
an exemption from federal drug laws [13]. Still, the federal
government continues to set unnecessary roadblocks in
scaling up SIFs in Canada. The introduction of Bill C-2,
known as the Respect for Communities Act, requires local
community and police support before a new SIF can be
implemented and gives the federal Minister of Health sole
authority in approving new SIFs to operate under the
exemption [14]. In essence, the government is putting
‘NIMBYism’ and policing interests ahead of public health.
If this new legislation is reintroduced and passed, appli-
cants will face significant obstacles in attempting to open
SIFs across Canada. This could have the effect of
preventing IDU from accessing low-barrier health
services and will thereby threaten the health and lives of
some of Canada’s most vulnerable citizens.
The evidence in support of harm reduction programs
only continues to grow, as does the evidence showing
that harm reduction programs do not exacerbate indi-
vidual and community drug use patterns. It is clear that
programs like Insite save lives and support rather than
undermine treatment efforts by connecting individuals
to various forms of addiction treatment. Sadly, despite
the evidence from Vancouver showing that the harm
reduction response served to significantly reduce drug-
related harms without increasing drug use locally, barriers
to implementing harm reduction programs in Canada
remain. These barriers, all social and political in na-
ture, have immense potential to exacerbate preventablehuman suffering and place a massive and unnecessary
burden on the Canadian healthcare system.
Conclusion
The time to heed the recommendations of the world’s
leading health bodies has come. Tired arguments against
harm reduction persist, but these come from those who
ignore evidence and put ideology and politics ahead of
public health. It can no longer be argued, in a compel-
ling fashion, that harm reduction exacerbates drug use
and undermines treatment efforts. The evidence from
Vancouver and elsewhere clearly shows that harm reduc-
tion programs typically do what they are designed to
do - they reduce drug-related harm, support addiction
treatment efforts, and thereby occupy a well-deserved
space with the continuum of programs and services
offered to IDU.
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